Healthcare diagnostic company Cerba Research disclosed on Thursday that its scientists have developed two new COVID-19 exploratory tools to help its clinical research customers develop tailored vaccines and treatments for COVID-19 and other infectious diseases.

Based on the nasopharyngeal ongoing patient samples, the tools are available and efficient on clinical specimens. Furthermore, this whole-genome sequencing in NGS assay is available for other viruses responsible for respiratory diseases like influenza viruses.

The company's In Vitro Diagnostic (IVD) division supported The French Public Health Agency (Santé Publique France) in a prospective COVID-19 seroprevalence study now identified as a major partner for epidemiological studies with the French Government.

According to the company, the new exploratory tools will enhance viral load measurement for SARS-CoV-2 using digital droplet PCR as well as enable whole-genome sequencing in NGS of the SARS-CoV-2 and other respiratory viruses.